Headquartered in Melville, NY, Henry Schein Inc. (HSIC - Free Report) is a global leading provider of healthcare products and services. The company serves office-based dental, medical and animal health practitioners, dental laboratories, government as well as institutional health care clinics and other alternate-care sites. Presently, Henry Schein serves more than 1 million customers and has operations in 28 countries. The company entered the prestigious Standard & Poor's (S&P) 500 Index in Mar, 2015.
Currently, Henry Schein has a Zacks Rank #2 (Buy) but that could change following its impressive first quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate remained steady at $1.66 per share over the last 60 days. Henry Schein’s adjusted earnings per share of $1.76 beat this estimate by 2.4%.
Revenues: Henry Schein posted revenues of $2.92 billion, ahead of the Zacks Consensus Estimate for revenues of $2.83 billion.
Key Stats: Revenues in the first quarter derived from Henry Schein’s Dental segment grew 7.9% year over year to $1.40 billion, while Animal Health segment recorded sales of $812.9 million, up 5.4% compared with the prior-year quarter. Revenues from Medical segment increased 11.3% year over year to $598.9 million, while sales from Technology and Value-added services segment grew 4.2% to $105.9 million.
Major Factors: Per management, the markets that Henry Schein serves are growing in a healthy manner and all its four global segments gained solid market share during the quarter. The company affirmed adjusted EPS guidance for 2017.
Stock Price: Following the earnings release, share prices did not show any significant movement in the pre-market trading session.
Check back later for our full write up on this Henry Schein earnings report later!
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth.
Download this IPO Watch List today for free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Headquartered in Melville, NY, Henry Schein Inc. (HSIC - Free Report) is a global leading provider of healthcare products and services. The company serves office-based dental, medical and animal health practitioners, dental laboratories, government as well as institutional health care clinics and other alternate-care sites. Presently, Henry Schein serves more than 1 million customers and has operations in 28 countries. The company entered the prestigious Standard & Poor's (S&P) 500 Index in Mar, 2015.
Currently, Henry Schein has a Zacks Rank #2 (Buy) but that could change following its impressive first quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate remained steady at $1.66 per share over the last 60 days. Henry Schein’s adjusted earnings per share of $1.76 beat this estimate by 2.4%.
Revenues: Henry Schein posted revenues of $2.92 billion, ahead of the Zacks Consensus Estimate for revenues of $2.83 billion.
Key Stats: Revenues in the first quarter derived from Henry Schein’s Dental segment grew 7.9% year over year to $1.40 billion, while Animal Health segment recorded sales of $812.9 million, up 5.4% compared with the prior-year quarter. Revenues from Medical segment increased 11.3% year over year to $598.9 million, while sales from Technology and Value-added services segment grew 4.2% to $105.9 million.
Major Factors: Per management, the markets that Henry Schein serves are growing in a healthy manner and all its four global segments gained solid market share during the quarter. The company affirmed adjusted EPS guidance for 2017.
Stock Price: Following the earnings release, share prices did not show any significant movement in the pre-market trading session.
Check back later for our full write up on this Henry Schein earnings report later!
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth.
Download this IPO Watch List today for free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on HSIC - FREE